{"id":"NCT05763823","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)","officialTitle":"A Phase 3, Open Label, Single-Arm Clinical Trial to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) for the Prevention of Clinically Significant Cytomegalovirus (CMV) Infection in Chinese Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-03-24","primaryCompletion":"2024-04-18","completion":"2024-04-18","firstPosted":"2023-03-10","resultsPosted":"2025-03-25","lastUpdate":"2025-03-25"},"enrollment":120,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Cytomegalovirus Infection"],"interventions":[{"type":"DRUG","name":"Letermovir","otherNames":["MK-8228"]}],"arms":[{"label":"Letermovir","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of a once-a-day oral or intravenous (IV) dose of Letermovir (MK-8228) in Chinese adult hematopoietic stem cell transplant (HSCT) recipients for the prevention of clinically significant cytomegalovirus (CMV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Clinically Significant Cytomegalovirus (CMV) Infection up to Week 24 Post-Transplant","timeFrame":"Up to Week 24 post-transplant (approximately 6 months)","effectByArm":[{"arm":"Letermovir","deltaMin":32,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":21,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://www.merckclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":70,"n":120},"commonTop":["Hypokalaemia","Vomiting","Pyrexia","Nausea","White blood cell count decreased"]}}